

Recd. 11-17



CHEMICAL MANUFACTURERS ASSOCIATION

→ JVL Here we go again.
Rec. fax to Mond, P&PD &
Poly U (re TRI, butadiene
& TDI) to ask if they are
prepared to undertake necessary
effort within deadlines.
Also fax to J. Ashby for
info.

RECEIVED

NOV 19 1986

November 10, 1986

File
CMA

HEALTH AND SAFETY DEPT

TO: HEALTH AND SAFETY CONTACTS OF CMA MEMBER COMPANIES

FROM: Nancy G. Doerrer *N. G. Doerrer*
Manager, Health, Safety and Chemical Regulations

SUBJECT: IARC's Classification of Potential Chemical Carcinogens: March
1987 Monograph Meetings

As part of a chemical industry initiative to promote the development and application of sound scientific principles, CMA requests your continued participation in the 1986-1987 IARC Monograph program.

BACKGROUND

The Chemical Manufacturers Association has been invited to nominate an observer to participate in two upcoming meetings of the International Agency for Research on Cancer (IARC).

Since July 1986, many of you have assisted CMA in evaluating key industrial chemicals in preparation for IARC Monograph meetings to be held 2-9 December 1986 in Lyon, France. At that time a working group of experts chosen by IARC will assess the activity of approximately 200 chemicals/exposures in short-term tests. Dale W. Matheson, Ph.D., of Stauffer Chemical Company will attend the December meeting as the official CMA Observer. Richard H. McKee, Ph.D., of Exxon Biomedical Sciences, Inc., will serve as the Alternate. Final preparations for the December meeting are well underway.

At a second meeting, to be held 10-17 March 1986 in Lyon, the degrees of evidence for carcinogenicity in humans and experimental animals will be assessed for the 200 chemicals/exposures. An overall evaluation of carcinogenic risk to humans will then be made based on experimental and epidemiological data. The list of chemicals/exposures is attached for your review (Attachment 1). These substances have previously been evaluated by IARC in Volumes 1-41 of the Monographs, but are now undergoing a second review.

OLI 4296

INDUSTRY PARTICIPATION

The CMA Health and Safety Committee's IARC Work Group is organizing industry participation in the March 1987 meeting. The number of chemicals and short time period for assessment of this list has dictated a method of action that requires full CMA member company participation. The following schedule has been constructed to prepare for effective scientific input at this important meeting:

DEADLINE: DECEMBER 1, 1986

- o Identify chemicals/exposures on the list (Attachment 1) that are of specific concern to your company.
- o Identify company expert(s) to assess the health effects literature and evaluate the carcinogenic data on chemicals of concern to your company. Return the attached form (Attachment 2) to CMA by December 1, 1986.
- o Nominate the CMA Observer to attend the March 1987 IARC Monograph meetings. The CMA Observer will not have a vote at the upcoming Monograph meetings, but will have the opportunity to contribute to discussions concerning the scientific evidence for classifying chemicals as carcinogens. The nomination of this observer will consist of careful selection from a list of names generated by representatives of CMA member companies. The CMA IARC Work Group encourages you to suggest potential nominees. H. Vainio, M.D., Chief of IARC's Unit of Carcinogen Evaluation and Identification, has requested that CMA submit the name of the industry observer to IARC by 31 December 1986.

DEADLINE: DECEMBER 15, 1986

- o Submit to CMA a bibliography of recently published animal and epidemiological information relevant to the carcinogenic assessment of chemicals of concern to your company. (Dr. Vainio recently made this specific request in a letter to CMA of 29 October 1986. By "recently published," we interpret Dr. Vainio's request to mean relevant articles published since the IARC Monograph in question was issued.)

DEADLINE: JANUARY 14, 1987

- o Submit to CMA an executive summary (using the format outlined in Attachment 3) describing IARC's assessment of the chemical/exposure in question, your assessment, and a full bibliography, including unpublished studies.

A logical method for arriving at the conclusions in your executive summary is as follows:

OLI 4297

Begin your review by locating the appropriate IARC Monograph(s) in which the original IARC carcinogenicity evaluation was described. By referring to the cumulative index at the back of the latest volume of the IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, you will easily access the appropriate Monograph(s).

Next, identify IARC's conclusions on a given chemical's carcinogenic potential. These conclusions will be expressed as "degrees of evidence" for carcinogenicity from studies in humans, in experimental animals, and from short-term tests. An overall evaluation of carcinogenic risk to humans may have been made for chemicals assessed in Volumes 1-29. These evaluations appear in Supplement 4 of the IARC Monographs (October 1982) as classifications into Groups 1, 2a, 2b or 3. (Refer to the "Preamble" to each Monograph for an explanation of the "degrees of evidence" and the groupings.)

CMA suggests that you review the appropriate IARC Monograph for accurate interpretation and inclusion of relevant information. Identify instances where you believe IARC may have misinterpreted the evidence. Secondly, identify key information not considered by IARC, i.e. data that was overlooked at the time of consideration by the IARC Committee and/or new information that has been developed since the Monograph was published.

CMA contends that published and unpublished data should be reviewed in IARC evaluations. IARC's policy is to consider only published information; nevertheless, this policy does not preclude the chemical industry from including valid, high quality industrial test data in our written submission of chemical reviews to IARC. In the event that you find key information that is new to the IARC carcinogen evaluation, consider submitting the data for publication to a peer-reviewed journal or some other written public forum. Taking this step assures that the data will be officially considered by the IARC Committee.

Although it may be unrealistic to expect reclassifications for chemicals in Group 1, it is nevertheless important to review any new or unpublished information previously unavailable to the IARC Working Groups.

At the March 1987 meetings, IARC will make "... evaluations of the degrees of evidence for carcinogenicity in humans and experimental animals ... for these chemicals and exposures and an overall evaluation of carcinogenic risk to humans will be made based on experimental and epidemiological data." To assist you in making your own evaluation, CMA suggests that you review two papers:

- a) Review and Recommendations for the Revision of the Preamble and Criteria of the IARC Monographs, CMA/AIHC/API/NACA/FMA, July, 1986 (recently sent to you under separate cover).
- b) Criteria for Identifying and Classifying Carcinogens, Mutagens and Teratogens, CMA/SOCMA/CEFIC/CCPA. In press, Reg. Toxicol. Pharmacol., December 1986.

CMA
Health and Safety Contacts
November 10, 1986
Page 4

Please contact me if you need copies of either of these documents.

Finally, write an executive summary on your findings, and include a full bibliography. Retain your file of collected articles, manuscripts or other forms of information at your office for future reference by the CMA IARC Work Group and the CMA Observer.

CMA anticipates that in your executive summaries you will divulge no confidential information. If such information is included, please designate it with a CBI notation.

* * * * *

CMA recognizes that there may be significant overlap in company interests in a given chemical. When we receive your list of chemicals and names of company experts, we will put you in touch with other member companies who have expressed the same interest so that you may equitably distribute the task of literature searching and carcinogen evaluation.

If you are interested in having your company's chemicals represented at the March 1987 IARC Monograph meetings, please make every effort to meet the deadlines cited in this memo.

I can be reached at 202/887-1282 with your questions or comments. I look forward to hearing from you.

Attachments

cc: IARC PROJECT PARTICIPANTS: December 1986 IARC Monograph Meetings
CMA Health and Safety Committee

OLI 4299

**IARC MONOGRAPHS ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS
TO HUMANS: CHEMICALS AND INDUSTRIAL PROCESSES ASSOCIATED WITH CANCER
IN HUMANS: UPDATING OF SUPPLEMENT 4 (PART I & PART II)**

TENTATIVE LIST OF SUBSTANCES AND EXPOSURES TO BE CONSIDERED

(At IARC Monograph Meetings December 2-9, 1986, and March 10-17, 1987)

Exposure	Exposure
Acetaldehyde	Benzidine-based dyes: Direct Black 38 Direct Blue 6 Direct Brown 95
Acrolein	Beryllium and beryllium compounds
Acrylonitrile	Betel quid with and without tobacco (chewing) Betel leaf Areca nut
Actinomycin D	N,N'-Bis(2-chloroethyl)-2-naphthyl- amine (Chlornaphazine)
Adriamycin	Bischloroethyl nitrosourea (BCNU)
Aflatoxins	Bis(chloromethyl)ether and technical- grade chloromethyl methyl ether
Aldrin	Bitumens
Aluminium production	Bleomycins
4-Aminobiphenyl	Boot and shoe manufacture and repair
Amitrole	Bracken fern
Anaesthetics, volatile	1,3-Butadiene
Analgesic mixtures containing phenacetin Phenacetin	1,4-Butanediol dimethanesulphonate (Myleran)
Aniline (and its hydrochloride)	Cadmium and cadmium compounds
Arsenic and arsenic compounds	Carbon blacks
Asbestos	Carbon tetrachloride
Attapulgate	Carpentry and joinery
Auramine, manufacture of Auramine	Chemotherapy for lymphomas: MOPP, etc.
Azathioprine	Chlorambucil OLI 4300
Benzene	Chloramphenicol
Benzidine	Chlordane/Hentachlor

Exposure

Chlorinated toluenes, production of:
Benzal chloride
Benzotrichloride
Benzoyl chloride
Benzyl chloride

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)

Chloroform

Chlorophenols

2,4-Dichlorophenol
Pentachlorophenol
2,3,4,6-Tetrachlorophenol
2,4,5-Trichlorophenol
2,4,6-Trichlorophenol

Chloroprene

Cholesterol

Chromium and chromium compounds

ortho-Chrysoidine

Cisplatin

Clofibrate

Coal gasification

Coal-tar pitches

Coal-tars

Coke production

Creosotes

Cyclanates

Cyclophosphamide

Dacarbazine

Dapsone

DDT

Diazepam

1,2-Dibromo-3-chloropropane

Exposure

ortho-Dichlorobenzene and
para-Dichlorobenzene

3,3'-Dichlorobenzidine

Dichloromethane

1,3-Dichloropropene

Dieldrin

Diethyl sulphate

3,3'-Dimethoxybenzidine (ortho-
Dianisidine)

Dimethylcarbamoyl chloride

Dimethyl sulphate

1,4-Dioxane

Epichlorohydrin

Erionite

Ethylene dibromide

Ethylene oxide

Ethylene thiourea

Fluorides (inorganic, in drinking-
water)

5-Fluorouracil

Formaldehyde

Furniture and cabinet making

Haematite mining, underground (with
exposures to radon)
Haematite (iron oxide)

Hexachlorobenzene

Hexachlorocyclohexane

Hydralazine OLI 4301

Hydrazine

Iron and steel founding

Exposure

Iron dextran complex

Isonicotinic acid hydrazide

Isopropyl alcohol manufacture
(strong-acid process)

Isopropyl alcohol

Isopropyl oils

Lead and lead compounds

Leather dusts

Leather goods manufacture

Leather tanning and processing

Lumber and sawmill industry

Magenta, manufacture of
Magenta

Melphalan

6-Mercaptopurine

Methotrexate

5-Methoxypsoralen (+ UVR)

6-Methoxypsoralen (+ UVR)

Methyl bromide

4,4'-Methylene bis(2-chloroaniline)
(MDCA)

4,4'-Methylene bis(2-methylaniline)

N-Methyl-N'-nitro-N-nitrosoguanidine

Metronidazole

Mineral oils

Mustard gas

1-Naphthylamine

2-Naphthylamine

1-Naphthylthiourea

Exposure

Nickel refining
Nickel and nickel compounds

Nitrogen mustard

Ochratoxin A

Oxymetholone

Phenazopyridine (and its
hydrochloride)

Phenelzine

Phenobarbital

Phenoxyacid herbicides
2,4-D and esters
2,4-DP
MCPA
MCPB
Silvex
2,4,5-T and esters

Phenylbutazone

N-Phenyl-2-naphthylamine

Phenytoin

Polybrominated biphenyls

Polychlorinated biphenyls

Prednisone

Procarbazine hydrochloride

Propylene oxide

Propylthiouracil

Pulp and paper manufacture

Reserpine

Rubber industry

Saccharin

Sepiolite

Exposure

Sex hormones:

Combined oral contraceptives
Sequential oral contraceptives
Other oestrogen-progestin combinations

Androgens:

Testosterone

Oestrogens:

Chlorotrianisene
Conjugated oestrogens
Dieneestrol
Diethylstilboestrol
Diethylstilboestrol dipropionate
Ethinylloestradiol
Hexoestrol
Mestranol
Oestradiol-17 α and esters
Oestriol
Oestrone and oestrone benzoate

Progestins:

Chlormadinone acetate
Dimethisterone
Ethinodiol diacetate
17 α -hydroxyprogesterone caproate
Lynoeestrenol
Medroxyprogesterone acetate
Megestrol acetate
Norethisterone
Norethisterone acetate
Norethynodrel
Norg strel
Prog sterone

Other:

Clomiphene
Clomiphene citrate

Shale-oils

Silica

Smoked ss tobacco products

Soots (and soot extracts)

Spiroolactone

Styrene

Sulfafurazole

Sulfamethoxazole

Talc

Exposure

Tetrachlorodibenzo-para-dioxin
(TCDD)

1,1,2,2-Tetrachloroethane

Tetrachloroethylene

Tobacco smoke

2,4- and 2,6-Toluene diisocyanates

ortho-Toluidine

Treosulphan

Trichloroethylene

4,5',8-Trimethylpsoralen (+ UVR)

Tris(aziridinyl)-para-benzoquinone
(Triaziquone)

Tris(1-aziridinyl) phosphine sulphide:
(Thiotepa)

Uracil mustard

Vinblastine sulphate

Vincristine sulphate

Vinyl chloride

Vinylidene chloride

Wollastonite

Wood dusts